Literature DB >> 24125564

Pure akinesia: a kinematic analysis in a case responsive to rotigotine.

R Di Fabio, M Serrao, F Pierelli, G Fragiotta, G Sandrini.   

Abstract

A patient with pure akinesia is described. This rare gait disorder, poorly responsive to therapy, is characterized by gait impairment which may be associated with handwriting and speech difficulties, in the absence of further signs of extrapyramidal involvement. Here, we report the improvement in a patient suffering from pure akinesia after low doses of rotigotine, a non-ergolinic dopamine agonist, detailing the kinematic analysis before and after the treatment. After therapy, an improvement in all of the gait parameters, particularly gait speed, was observed with a trend toward normalization. Our case report suggests that rotigotine may be a therapeutic option in cases of pure akinesia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125564      PMCID: PMC3812732          DOI: 10.11138/FNeur/2013.28.2.133

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  11 in total

Review 1.  The pharmacologic treatment of gait ignition failure.

Authors:  O Rascol; N Fabre; C Brefel-Courbon; J L Montastruc
Journal:  Adv Neurol       Date:  2001

2.  Improvement with duloxetine in primary progressive freezing gait.

Authors:  Francesca Morgante; Alfonso Fasano
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

Review 3.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

4.  Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine.

Authors:  S Miyata; T Hamamura; J Yoshinaga; Y Nakamura; T Imamura; A Hikiji; S Kuroda
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

5.  Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy.

Authors:  H Yoshikawa; Y Oda; K Sakajiri; M Takamori; I Nakanishi; T Makifuchi; Y Ide; S Matsubara; N Mizushima
Journal:  Acta Neuropathol       Date:  1997-03       Impact factor: 17.088

6.  Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy.

Authors:  M Yamamoto; S Fujii; Y Hatanaka
Journal:  Clin Neuropharmacol       Date:  1997-08       Impact factor: 1.592

7.  Rasagiline improves freezing in a patient with primary progressive freezing gait.

Authors:  Francisco Coria; María del Puig Cozar-Santiago
Journal:  Mov Disord       Date:  2008-02-15       Impact factor: 10.338

8.  Pure akinesia: an atypical manifestation of progressive supranuclear palsy.

Authors:  H Matsuo; H Takashima; M Kishikawa; I Kinoshita; M Mori; M Tsujihata; S Nagataki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

9.  The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.

Authors:  Kristin B Dupre; Karen L Eskow; Giselle Negron; Christopher Bishop
Journal:  Brain Res       Date:  2007-05-08       Impact factor: 3.252

10.  Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy.

Authors:  David R Williams; Janice L Holton; Kate Strand; Tamas Revesz; Andrew J Lees
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

View more
  1 in total

1.  Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.

Authors:  Ken Ikeda; Takehisa Hirayama; Takanori Takazawa; Kiyokazu Kawabe; Yasuo Iwasaki
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.